Since MELK inhibition in breast cancer was shown to activate the ATM-CHK2 pathway and thus suggested to reactivate the DNA damage response, we expected that combining OTSSP167 with doxorubicin would enhance the anti-lymphoma activity of this topoisomerase II inhibitor38. Here, CHEK2 is linked to breast carcinoma.